Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKD regimen after suboptimal frontline VRd/VCD induction in multiple myeloma
ChiCTR2500099167Phase 4Not yet recruiting
- Sponsor
- People's Hospital of Xinjiang Uygur Autonomous Region
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daratumumab, carfilzomib and dexamethasone in multiple myeloma (MM), sponsored by People's Hospital of Xinjiang Uygur Autonomous Region. Primary endpoint: Very good partial response rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
daratumumabcarfilzomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500099167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099167.